Author Of 3 Presentations
LB1247 - Clinical features of COVID-19 in patients with neuromyelitis optica spectrum disorders (ID 2133)
- S. Apóstolos-Pereira
- L. Ferreira
- N. Sousa
- G. Martins
- J. D’almeida
- M. Pitombeira
- L. Mendes
- T. Fukuda
- L. Rocha
- H. Cabeça
- B. Oliveira
- C. Vieira Stella
- E. Oliveira
- L. Amorim
- A. Castro
- A. Gomes Neto
- G. Silva
- L. Bueno
- M. Machado
- R. Dias-Carneiro
- R. Dias
- A. Moreira
- A. Piccolo
- A. Grzesiuk
- A. Muniz
- C. Disserol
- C. Vasconcelos
- D. Diniz
- D. Kaimen-Maciel
- E. Comini-Frota
- F. Rocha
- G. Sciascia Do Olival
- G. Santos
- H. Ruocco
- H. Siqueira
- H. Sato
- H. Soares Neto
- J. Figueiredo Jr
- L. Calia
- L. Scolari
- L. Melges
- M. Gonçalves
- M. Pimentel
- M. Dourado Junior
- M. De Castro Ribeiro
- O. Arambula
- P. Gama
- R. Menon
- R. Thomaz
- R. Morales
- S. Gomes
- S. Sobreira
- S. Alves-Leon
- S. Machado
- T. Ribeiro
- V. Pereira
- V. Costa
- M. Perin
- A. Nóbrega Junior
- Y. Fragoso
- E. Donadi
- T. Adoni
- M. Ferreira
- D. Callegaro
- M. Mendes
- D. Brum
- F. Von Glehn
Abstract
Background
Brazil is currently considered one of the main epicenters of the coronavirus disease 2019 (COVID-19). There are many concerns related to neuromyelitis optica spectrum disorders (NMOSD) patients. In addition to the older age of onset, higher disability and the higher rate of hospitalization compared to MS, many of the commonly used preventive therapies for NMOSD are cell depleting immunosuppressants with increased risk of viral and bacterial infections.
Objectives
To describe the frequency and clinical characteristics of COVID-19 in neuromyelitis optica spectrum disorder (NMOSD) patients in Brazil.
Methods
The Brazilian Study Group NMOSD of the Brazilian Academy of Neurology has set up the registration of COVID-19 cases in NMOSD patients, using a designed web-based case report form, encompassing neuroimmunology centers and individual neurologists across the country. Data collected between March 19thand July 31th 2020 were uploaded at the REDONE.br platform. Inclusion criteria were: (i) NMOSD diagnosis according to 2015 International Panel; (ii) confirmed SARS-Cov-2 infection (RT-PCR or serology) or clinical suspicion of COVID-19 diagnosed according to CDC/CSTE case definition. Demographic data, NMOSD clinical characteristics pre and post infection, comorbidities, immunosuppressive treatment, COVID-19 clinical features and severity were described.
Results
Among the 2,061 NMOSD patients inscribed at the REDONE.br platform, 34 patients (29 women) aged 37.1 years (range 8-77), with disease onset at 31.2 years (range 4-69) and disease duration of 5.9 years (range 0.2-20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibiting mild disease was treated at home (76.5%) and 4 patients needed treatment at intensive care units (severe cases); one patient died. Four patients had NMOSD relapse during the infection; one with partial recovery.
Conclusions
The clinical features of COVID-19 in NMOSD patients were described, stressing the combination of comorbidities and immunosuppression. Mild COVID-19 was the main presentation. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 outcome.
P1049 - "Quality of life in multiple sclerosis. Beyond disability: Resilience, fatigue, anxiety and depression as determinants" (ID 1374)
Abstract
Background
Previous studies suggest that fatigue, depression, anxiety and disability affect quality of life in Multiple sclerosis. Resilience has emerged as a modulator of quality of life. There are few studies exploring the relationship between quality of life and resilience in Multiple Sclerosis patients in the context of recognized determinants as fatigue, neuropsychiatric symptoms and disability.
Objectives
To evaluate relationship between quality of life and resilience, disability, fatigue, anxiety and depression in patients with Multiple Sclerosis.
Methods
52 Multiple Sclerosis patients were evaluated with the Functional Assessment Multiple Sclerosis for quality of life, Connor-Davidson 25 Resilience Scale, Modified Fatigue Impact Scale, Hospital Anxiety and Depression Scale, Functional Independence Measure, Symbol digit modalities test and Expanded Disability Status Scale.
Results
Patients with higher scores of resilience and functional independence had higher Quality of life scores. Patients with higher fatigue, anxiety and depression had lower quality of life scores. Expanded Disability Status Scale and duration of the disease were unrelated to quality of life.
Conclusions
Resilience, functional independence, fatigue, anxiety and depression are independently related and determine the variability of quality of life. Look beyond disability is important for the improvement of Quality of life in patients with Multiple Sclerosis.
P1053 - "Resilience in multiple sclerosis relationship with disability, fatigue, anxiety, depression and cognition" (ID 1346)
Abstract
Background
Resilience is a construct defined as the capability of positive adaptation despite adversity. In the context of wellness research in Multiple Sclerosis (MS), resilience has been cited as one of the factors that may mediate emotional wellness. In patients with MS there are few studies on resilience and factors correlated with it.
Objectives
To evaluate resilience in MS patients and its relationship with disability, fatigue, anxiety, depression and cognition.
Methods
52 Multiple Sclerosis patients were evaluated in a longitudinal study using Connor-Davidson 25 Resilience Scale, Modified Fatigue Impact Scale, Hospital Anxiety and Depression Scale, Functional Independence Measure (FIM), Symbol digit modalities test (SDMT) for cognition and Expanded Disability Status Scale (EDSS).
Results
EDSS score (rs= -0.29; p= 0.041), fatigue (r= -0,35; p= 0,012), anxiety (rs= -0.41; p<0.05) and depression (rs= -0.52; p<0.001) were negatively correlated to resilience. Cognition evaluated by SDMT (r= 0,35; p=0,011) and Independence measured by FIM (r= 0.37; p<0.01) were positively correlated to resilience. In multiple regression analyses, depression and cognition were retained as independently factors related to resilience.
Conclusions
Resilience in MS patients could be determined by depression and cognitive status. Seeing beyond physical disability and targeting depression is a possible way to improve resilience and consequently emotional wellness and quality of life in MS patients.